You are here

Development of TLR8 inhibitors for treatment of autoimmune diseases

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI096641-01A1
Agency Tracking Number: R43AI096641
Amount: $599,016.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-123
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2929 7TH ST, STE 100
BERKELEY, CA -
United States
DUNS: 964173801
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CRISTIANA GUIDUCCI
 (510) 665-7267
 cguiducci@dynavax.com
Business Contact
 ROBERT COFFMAN
Phone: (510) 665-7224
Email: rcoffman@dynavax.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Autoimmune diseases develop when the adaptive immune response targets self-antigens, leading to inflammation and tissue destruction. The innate immune system faces the same fundamental challenge as the adaptive immune system - distinguishing self from non-self antigens - and there is now considerable evidence that recognition of self nucleic acids through toll-like receptors (TLRs) can contribute significantly to sterile inflammation and autoimmunity, with the clearest example being the role played by TLR9 and TLR7 in the pathogenesis of systemic lupus erythematosus (SLE). The major exception has been TLR8, despite its ability to stimulate important inflammatory cytokines such as IL6 and TNF-1, and its expression by multiple cell types involved in inflammatory diseases. The lack of useful animal rodent models, a consequence of the very different ligand specificity of human TLR8 and its rodent orthologs, has proven to be a major limitation in the study of TLR8 biology. Mouse TLR8 lacks the capability of responding to ssRNA ligands, RNA viruses, or small molecules; all of which have been shown to activate human TLR8. We have developed new tools that we hope will help better understand the biology of TLR8. The key objective ofthis proposal is thus to identify and characterize a lead TLR8 inhibitory oligonucleotide suitable for IND-enabling preclinical and process-development studies. The principal activities will include: Identify an oligonucleotide-based inhibitor of humanTLR8 using in vitro assays with human primary cells, Define its specificity against the other TLR pathways, Test its activity in vivo in an acute model, Determine its ability to prevent a TLR8-dependent autoimmune disease in rodents. If successful, the data generated will provide the groundwork for a full-scale development program for a TLR8 inhibitor for autoimmune diseases. PUBLIC HEALTH RELEVANCE: Although many drugs targeting pro-inflammatory cytokines such as TNF have proven clinicallybeneficial, the mechanism underlying the production of these cytokines in various autoimmune diseases is still poorly understood. Our recent discovery is that a key innate receptor, Toll-Like Receptor (TLR) 8, can promote multi- organ autoimmune symptoms,including rheumatoid arthritis, when triggered in mice. We propose to develop a novel drug that inhibits this receptor and the subsequent pro-inflammatory response as a therapy for autoimmune diseases.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government